SALE EXTENDED
MarketBeat All Access
Start your 30-day free trial,
then continue your subscription for 50% off.
TODAY ONLY!
Claim Your Discount
×
S&P 500   3,639.66 (-2.80%)
DOW   29,296.79 (-2.11%)
QQQ   269.10 (-3.81%)
AAPL   140.09 (-3.67%)
MSFT   234.24 (-5.09%)
META   133.45 (-4.04%)
GOOGL   98.68 (-2.70%)
AMZN   114.56 (-4.77%)
TSLA   223.07 (-6.32%)
NVDA   120.76 (-8.03%)
NIO   13.76 (-6.84%)
BABA   81.24 (-3.65%)
AMD   58.44 (-13.87%)
T   14.94 (-2.48%)
MU   52.91 (-3.13%)
CGC   2.79 (-25.60%)
F   12.20 (-1.29%)
GE   64.56 (-2.51%)
DIS   97.16 (-2.88%)
AMC   6.53 (-8.29%)
PYPL   90.17 (-4.50%)
PFE   42.32 (-1.79%)
NFLX   224.75 (-6.36%)
S&P 500   3,639.66 (-2.80%)
DOW   29,296.79 (-2.11%)
QQQ   269.10 (-3.81%)
AAPL   140.09 (-3.67%)
MSFT   234.24 (-5.09%)
META   133.45 (-4.04%)
GOOGL   98.68 (-2.70%)
AMZN   114.56 (-4.77%)
TSLA   223.07 (-6.32%)
NVDA   120.76 (-8.03%)
NIO   13.76 (-6.84%)
BABA   81.24 (-3.65%)
AMD   58.44 (-13.87%)
T   14.94 (-2.48%)
MU   52.91 (-3.13%)
CGC   2.79 (-25.60%)
F   12.20 (-1.29%)
GE   64.56 (-2.51%)
DIS   97.16 (-2.88%)
AMC   6.53 (-8.29%)
PYPL   90.17 (-4.50%)
PFE   42.32 (-1.79%)
NFLX   224.75 (-6.36%)
S&P 500   3,639.66 (-2.80%)
DOW   29,296.79 (-2.11%)
QQQ   269.10 (-3.81%)
AAPL   140.09 (-3.67%)
MSFT   234.24 (-5.09%)
META   133.45 (-4.04%)
GOOGL   98.68 (-2.70%)
AMZN   114.56 (-4.77%)
TSLA   223.07 (-6.32%)
NVDA   120.76 (-8.03%)
NIO   13.76 (-6.84%)
BABA   81.24 (-3.65%)
AMD   58.44 (-13.87%)
T   14.94 (-2.48%)
MU   52.91 (-3.13%)
CGC   2.79 (-25.60%)
F   12.20 (-1.29%)
GE   64.56 (-2.51%)
DIS   97.16 (-2.88%)
AMC   6.53 (-8.29%)
PYPL   90.17 (-4.50%)
PFE   42.32 (-1.79%)
NFLX   224.75 (-6.36%)
S&P 500   3,639.66 (-2.80%)
DOW   29,296.79 (-2.11%)
QQQ   269.10 (-3.81%)
AAPL   140.09 (-3.67%)
MSFT   234.24 (-5.09%)
META   133.45 (-4.04%)
GOOGL   98.68 (-2.70%)
AMZN   114.56 (-4.77%)
TSLA   223.07 (-6.32%)
NVDA   120.76 (-8.03%)
NIO   13.76 (-6.84%)
BABA   81.24 (-3.65%)
AMD   58.44 (-13.87%)
T   14.94 (-2.48%)
MU   52.91 (-3.13%)
CGC   2.79 (-25.60%)
F   12.20 (-1.29%)
GE   64.56 (-2.51%)
DIS   97.16 (-2.88%)
AMC   6.53 (-8.29%)
PYPL   90.17 (-4.50%)
PFE   42.32 (-1.79%)
NFLX   224.75 (-6.36%)
NASDAQ:CDTX

Cidara Therapeutics - CDTX Stock Forecast, Price & News

$0.64
-0.01 (-1.55%)
(As of 10/7/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.63
$0.65
50-Day Range
$0.55
$0.81
52-Week Range
$0.40
$1.90
Volume
104,723 shs
Average Volume
367,928 shs
Market Capitalization
$43.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

Cidara Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
843.0% Upside
$6.00 Price Target
Short Interest
Healthy
0.86% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.85
Upright™ Environmental Score
News Sentiment
0.92mentions of Cidara Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$35,625 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.69) to ($0.08) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.39 out of 5 stars

Medical Sector

215th out of 1,072 stocks

Biological Products, Except Diagnostic Industry

29th out of 171 stocks

CDTX stock logo

About Cidara Therapeutics (NASDAQ:CDTX) Stock

Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.

Receive CDTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cidara Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CDTX Stock News Headlines

H.C. Wainwright Reaffirms Their Buy Rating on Cidara Therapeutics (CDTX)
Cidara Therapeutics Inc
Recap: Cidara Therapeutics Q1 Earnings
See More Headlines
Receive CDTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cidara Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CDTX Company Calendar

Last Earnings
8/09/2022
Today
10/07/2022
Next Earnings (Estimated)
11/09/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CDTX
Fax
N/A
Employees
89
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.00
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+843.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-42,470,000.00
Net Margins
-239.94%
Pretax Margin
-239.94%

Debt

Sales & Book Value

Annual Sales
$49.57 million
Book Value
$0.32 per share

Miscellaneous

Free Float
64,367,000
Market Cap
$43.94 million
Optionable
Optionable
Beta
1.47

Key Executives

  • Dr. Jeffrey L. Stein Ph.D. (Age 67)
    Pres, CEO & Exec. Director
    Comp: $836.4k
  • Dr. Taylor Sandison (Age 50)
    Chief Medical Officer
    Comp: $597.9k
  • Dr. Les Tari Ph.D.
    Chief Scientific Officer
  • Dr. Kevin M. Forrest Ph.D. (Age 45)
    Founder and Chief Strategy Officer
  • Dr. Preetam Shah M.B.A. (Age 49)
    Ph.D., CFO, Chief Bus. Officer & Principal Accounting Officer
  • Mr. Paul DaruwalaMr. Paul Daruwala (Age 53)
    Chief Operating Officer
  • Mr. Shane M. Ward (Age 47)
    Chief Legal Officer & Corp. Sec.
  • Ms. Allison Lewis CCP
    SPHR, VP of HR
  • Mr. James M. Balkovec
    Sr. VP of Research
  • Ms. Laura A. Navalta
    Sr. VP of Clinical Operations













CDTX Stock - Frequently Asked Questions

Should I buy or sell Cidara Therapeutics stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cidara Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CDTX shares.
View CDTX analyst ratings
or view top-rated stocks.

What is Cidara Therapeutics' stock price forecast for 2022?

4 Wall Street research analysts have issued 1 year price targets for Cidara Therapeutics' shares. Their CDTX share price forecasts range from $6.00 to $6.00. On average, they predict the company's share price to reach $6.00 in the next twelve months. This suggests a possible upside of 826.8% from the stock's current price.
View analysts price targets for CDTX
or view top-rated stocks among Wall Street analysts.

How have CDTX shares performed in 2022?

Cidara Therapeutics' stock was trading at $1.27 at the beginning of 2022. Since then, CDTX stock has decreased by 49.0% and is now trading at $0.6474.
View the best growth stocks for 2022 here
.

When is Cidara Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our CDTX earnings forecast
.

How were Cidara Therapeutics' earnings last quarter?

Cidara Therapeutics, Inc. (NASDAQ:CDTX) posted its quarterly earnings data on Tuesday, August, 9th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.28) by $0.09. The biotechnology company earned $6.22 million during the quarter, compared to analysts' expectations of $7.30 million. Cidara Therapeutics had a negative net margin of 239.94% and a negative trailing twelve-month return on equity of 1,522.85%.

What other stocks do shareholders of Cidara Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cidara Therapeutics investors own include Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Verastem (VSTM), Dynavax Technologies (DVAX), Micron Technology (MU), Exelixis (EXEL), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE) and Catalyst Pharmaceuticals (CPRX).

When did Cidara Therapeutics IPO?

(CDTX) raised $60 million in an initial public offering (IPO) on Wednesday, April 15th 2015. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Jefferies and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow Life Sciences, Needham and BTIG were co-managers.

What is Cidara Therapeutics' stock symbol?

Cidara Therapeutics trades on the NASDAQ under the ticker symbol "CDTX."

How do I buy shares of Cidara Therapeutics?

Shares of CDTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cidara Therapeutics' stock price today?

One share of CDTX stock can currently be purchased for approximately $0.65.

How much money does Cidara Therapeutics make?

Cidara Therapeutics (NASDAQ:CDTX) has a market capitalization of $44.70 million and generates $49.57 million in revenue each year. The biotechnology company earns $-42,470,000.00 in net income (profit) each year or ($1.09) on an earnings per share basis.

How can I contact Cidara Therapeutics?

Cidara Therapeutics' mailing address is 6310 NANCY RIDGE DRIVE SUITE 101, SAN DIEGO CA, 92121. The official website for the company is www.cidara.com. The biotechnology company can be reached via phone at (858) 752-6170 or via email at britchie@lifesciadvisors.com.

This page (NASDAQ:CDTX) was last updated on 10/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.